FYI: Biotech ETFs have been on fire in recent days, and that has nothing to do with the ongoing debate surrounding the health care bill. Instead, it’s about regulation—or the easing of regulation, that is.
The two main drivers of this recent rally both center on a positive regulatory backdrop—one that’s offering fundamental support to the segment as well as fueling upside in some breakthrough biotech companies.
Regards,
Ted
http://www.etf.com/sections/features-and-news/2-key-drivers-behind-biotech-etf-rally?nopaging=1
